Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”),